0001078274-21-000006.txt : 20211210 0001078274-21-000006.hdr.sgml : 20211210 20211210170359 ACCESSION NUMBER: 0001078274-21-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211208 FILED AS OF DATE: 20211210 DATE AS OF CHANGE: 20211210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MYERS STEVEN S CENTRAL INDEX KEY: 0001078274 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33650 FILM NUMBER: 211486116 MAIL ADDRESS: STREET 1: 4695 MACAUTHUR COURT STREET 2: EIGHTH FLOOR CITY: NEWPORT BEACH STATE: CA ZIP: 92660 FORMER NAME: FORMER CONFORMED NAME: MEYERS STEVEN S DATE OF NAME CHANGE: 19990203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CALADRIUS BIOSCIENCES, INC. CENTRAL INDEX KEY: 0000320017 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 222343568 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 BUSINESS PHONE: 908-842-0100 MAIL ADDRESS: STREET 1: 110 ALLEN ROAD STREET 2: SECOND FLOOR CITY: BASKING RIDGE STATE: NJ ZIP: 07920 FORMER COMPANY: FORMER CONFORMED NAME: Caladrius Biosciences, Inc. DATE OF NAME CHANGE: 20150608 FORMER COMPANY: FORMER CONFORMED NAME: NeoStem, Inc. DATE OF NAME CHANGE: 20060906 FORMER COMPANY: FORMER CONFORMED NAME: PHASE III MEDICAL INC/DE DATE OF NAME CHANGE: 20030819 4 1 wf-form4_163917382551212.xml FORM 4 X0306 4 2021-12-08 0 0000320017 CALADRIUS BIOSCIENCES, INC. CLBS 0001078274 MYERS STEVEN S C/O CALADRIUS BIOSCIENCES, INC. 110 ALLEN ROAD, 2ND FLOOR BASKING RIDGE NJ 07920 1 0 0 0 Common Stock 2021-12-08 4 P 0 33785 0.8936 A 146839 D Common Stock 8434 I By Steven S Myers IRA Common Stock 1954 I By Steven S Myers Revocable Trust dated 12/1/2000 Common Stock 802 I By spouse The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8802 to $0.9000, inclusive. The reporting person undertakes to provide Caladrius Biosciences, Inc., any security holder of Caladrius Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Represents 37,735 unvested restricted stock awards granted under Issuer's 2018 Equity Incentive Compensation plan, which will vest on January 11, 2022. Steven S. Myers, By: /s/ Todd C. Girolamo, Esq., Attorney-in-Fact 2021-12-10